Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Pearl Therapeutics Stories

2012-05-14 06:27:07

In the news release, Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD, issued 14-May-2012 by Pearl Therapeutics over PR Newswire, we are advised by the company that the dateline date should read "May 14, 2012" rather than "May 14, 2011" as originally issued inadvertently. The complete, corrected release follows: Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients...

2012-04-03 02:27:09

REDWOOD CITY, Calif., April 3, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced that the company has successfully formulated and manufactured metered-dose inhalers (MDI) that deliver 300ng per actuation of glycopyrrolate (GP), a highly potent, long-acting muscarinic antagonist (LAMA) using its porous particle cosuspension technology. By breaking the microgram dose barrier, Pearl aims to evaluate completely the safety and efficacy profiles of GP, and other very potent inhaled...

2011-09-06 14:53:00

REDWOOD CITY, Calif., Sept. 6, 2011 /PRNewswire/ -- Pearl Therapeutics was named by FierceBiotech today as one of 2011's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's ninth annual Fierce 15 selection. "Pearl's veteran team has done a super job of raising the funds and doing clinical research to advance PT003 - an inhaled LAMA/LABA combination therapy - toward the market," says Ryan McBride, the executive...

2011-02-24 14:30:00

REDWOOD CITY, Calif., Feb. 24, 2011 /PRNewswire/ -- Pearl Therapeutics announced today the appointment of Chuck Bramlage to the position of president and chief executive officer. In addition, Mr. Bramlage will join the Company's Board of Directors. Both appointments were effective as of February 22, 2011. "Chuck brings almost 30 years of pharmaceutical and biotechnology leadership experience to Pearl," said James W. Young, PhD, chairman of the Pearl Board of Directors and venture partner...

2010-05-18 08:15:00

REDWOOD CITY, Calif., May 18 /PRNewswire/ -- Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI). The data were presented in a...